0 CHECKOUT

ImmunoGen, Inc. - Product Pipeline Review - 2015

  • ID: 3422649
  • August 2015
  • 42 pages
  • Global Markets Direct
1 of 3

ImmunoGen, Inc. - Product Pipeline Review - 2015

Summary

The report ‘ImmunoGen, Inc. - Product Pipeline Review - 2015’, provides an overview of the ImmunoGen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmunoGen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

ImmunoGen, Inc. Snapshot

ImmunoGen, Inc. Overview

Key Information

Key Facts

ImmunoGen, Inc. - Research and Development Overview

Key Therapeutic Areas

ImmunoGen, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

ImmunoGen, Inc. - Pipeline Products Glance

ImmunoGen, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

ImmunoGen, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

ImmunoGen, Inc. - Drug Profiles

coltuximab ravtansine

Product Description

Mechanism of Action

R&D Progress

IMGN-529

Product Description

Mechanism of Action

R&D Progress

mirvetuximab soravtansine

Product Description

Mechanism of Action

R&D Progress

huHER3-8

Product Description

Mechanism of Action

R&D Progress

IMGN-289

Product Description

Mechanism of Action

R&D Progress

IMGN-779

Product Description

Mechanism of Action

R&D Progress

ImmunoGen, Inc. - Pipeline Analysis

ImmunoGen, Inc. - Pipeline Products by Target

ImmunoGen, Inc. - Pipeline Products by Route of Administration

ImmunoGen, Inc. - Pipeline Products by Molecule Type

ImmunoGen, Inc. - Pipeline Products by Mechanism of Action

ImmunoGen, Inc. - Recent Pipeline Updates

ImmunoGen, Inc. - Dormant Projects

ImmunoGen, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AVE-1642

AVE-9633

cantuzumab ravtansine

coltuximab ravtansine

IMGN-388

lorvotuzumab mertansine

Oncolysin B

ImmunoGen, Inc. - Company Statement

ImmunoGen, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

ImmunoGen, Inc., Key Information

ImmunoGen, Inc., Key Facts

ImmunoGen, Inc. - Pipeline by Indication, 2015

ImmunoGen, Inc. - Pipeline by Stage of Development, 2015

ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2015

ImmunoGen, Inc. - Partnered Products in Pipeline, 2015

ImmunoGen, Inc. - Partnered Products/ Combination Treatment Modalities, 2015

ImmunoGen, Inc. - Phase II, 2015

ImmunoGen, Inc. - Phase I, 2015

ImmunoGen, Inc. - Preclinical, 2015

ImmunoGen, Inc. - Pipeline by Target, 2015

ImmunoGen, Inc. - Pipeline by Route of Administration, 2015

ImmunoGen, Inc. - Pipeline by Molecule Type, 2015

ImmunoGen, Inc. - Pipeline Products by Mechanism of Action, 2015

ImmunoGen, Inc. - Recent Pipeline Updates, 2015

ImmunoGen, Inc. - Dormant Developmental Projects,2015

ImmunoGen, Inc. - Discontinued Pipeline Products, 2015

ImmunoGen, Inc., Subsidiaries

List of Figures

ImmunoGen, Inc. - Pipeline by Top 10 Indication, 2015

ImmunoGen, Inc. - Pipeline by Stage of Development, 2015

ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2015

ImmunoGen, Inc. - Partnered Products in Pipeline, 2015

ImmunoGen, Inc. - Pipeline by Top 10 Target, 2015

ImmunoGen, Inc. - Pipeline by Top 10 Route of Administration, 2015

ImmunoGen, Inc. - Pipeline by Top 10 Molecule Type, 2015

ImmunoGen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.